Aveo RCC compound trends toward detrimental survival effect, again

Despite announcing plans to submit an NDA to FDA for its renal cell carcinoma compound in about six months, Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) lost $0.51 (20%) to $2.03 on Tuesday after reporting preliminary data late

Read the full 356 word article

How to gain access

Continue reading with a
two-week free trial.